Stockscreener 앱 받기
79.28
1.84%
-1.49
시간 외 거래:
79.90
0.62
+0.78%
Dexcom Inc 주식(DXCM)의 최신 뉴스
How volatile is DexCom Inc. stock compared to the marketCapitalize on high-yield stock opportunities - jammulinksnews.com
Is it the right time to buy DexCom Inc. stockCapitalize on emerging market sectors - jammulinksnews.com
Is DexCom Inc. stock overvalued or undervaluedExceptional portfolio growth - jammulinksnews.com
What analysts say about DexCom Inc. stockTriple-digit returns - jammulinksnews.com
What institutional investors are buying DexCom Inc. stockOverwhelming financial success - jammulinksnews.com
Is It Time to Buy DexCom at a Discount Before Growth Fully Materializes? - AInvest
DexCom Inc. Stock Analysis and ForecastOverwhelming profit margins - jammulinksnews.com
How many analysts rate DexCom Inc. as a “Buy”Fastest-growing stock picks - jammulinksnews.com
How does DexCom Inc. generate profit in a changing economyMaximize your portfolio’s earning potential - jammulinksnews.com
What are analysts’ price targets for DexCom Inc. in the next 12 monthsTop Growth Trend Scanner With High Returns - jammulinksnews.com
DexCom raises 2025 revenue guidance to $4.625B as type 2 non-insulin access expands - MSN
Does DexCom Inc. stock perform well during market downturnsInvest smarter with real-time trading signals - jammulinksnews.com
What is the risk reward ratio of investing in DexCom Inc. stockInvest like a pro with expert recommendations - jammulinksnews.com
Investors Hope for Bounce in DexCom Inc. After SelloffValue Investing Picks With Stability Outlined - metal.it
DexCom (DXCM) Receives 'Buy' Rating from Canaccord Genuity | DXC - GuruFocus
Commit To Purchase DexCom At $50, Earn 6.2% Using Options - Nasdaq
DexCom, Inc. (NASDAQ:DXCM) Q2 2025 Earnings Call Transcript - Insider Monkey
Raymond James Maintains Buy Rating for Dexcom with $102 Price Target - AInvest
DexCom (DXCM) Q2 Revenue Jumps 15% - The Globe and Mail
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Dexcom raises sales expectations, discusses G8 plans - MedTech Dive
DexCom stock price target raised to $106 from $105 at UBS - Investing.com Australia
DexCom (DXCM) Sees Target Price Upgrade Post-Quarterly Results - GuruFocus
Dexcom: Raymond James Keeps Strong Buy, PT Raised to $102 from $99. - AInvest
DexCom (DXCM) Receives a Price Target Boost from Baird - GuruFocus
DexCom Q2 Earnings Beat Expectations, Raises 2025 Revenue Outlook - AInvest
Diabetes Care Devices Market Size Projects USD 76.44 Billion by 2034 - GlobeNewswire Inc.
DexCom (DXCM) Price Target Raised by Oppenheimer to $102 | DXCM Stock News - GuruFocus
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise - Yahoo Finance
Dexcom, Inc. shares fall 4.70% premarket despite beating quarterly estimates and naming new CEO. - AInvest
DexCom Q2 2025 Earnings Call Transcript - MarketBeat
Dexcom Reports Strong Q2 2025 Growth and Leadership Change - TipRanks
DexCom Raises 2025 Revenue Guidance to $4.625B on Strong Type 2 Non-Insulin Access Growth - AInvest
Earnings call transcript: DexCom beats Q2 2025 expectations, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: DexCom beats Q2 2025 expectations, stock rises - Investing.com Australia
Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Dexcom to promote COO Jake Leach to CEO, succeeding Kevin Sayer - MassDevice
Dexcom's Earnings Beat and Leadership Transition: Strategic Leadership Continuity and Growth Sustainability in the Diabetes Tech Sector - AInvest
DexCom Beats Q2 Revenue Estimates, Raises Full-Year Guidance - AInvest
DexCom: Q2 Earnings Snapshot - San Francisco Chronicle
Dexcom beats estimates for quarterly results, names new CEO - TradingView
Dexcom CEO Kevin Sayer to step down - MedTech Dive
DexCom's Earnings Beat and Strategic Leadership Shift: A Catalyst for Sustained Growth in the CGM Market? - AInvest
Dexcom falls despite results beat, revenue outlook raise (DXCM) - Seeking Alpha
DexCom Inc (DXCM) Q2 2025 Earnings: EPS of $0.45 Beats Estimate, Revenue Surges to $1.157 Billion - GuruFocus
DexCom posts strong Q2 results, announces CEO change; Shares fall 4% - Investing.com Nigeria
DexCom Q2 2025 slides: 15% revenue growth, FDA clearance for extended-wear G7 - Investing.com Canada
Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan - Business Wire
DexCom (DXCM) Receives Target Price Upgrade from Barclays | DXCM Stock News - GuruFocus
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program | DXCM Stock News - GuruFocus
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program - The Joplin Globe
DexCom Inc. Shows Early Signs of Technical StrengthBuy Alerts With Low Risk Confirmation Noted - metal.it
DexCom Inc. Approaches Psychological Resistance LevelTop Gaining Picks With Entry Signals Identified - metal.it
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact? - MSN
Dexcom Unveils AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio - AInvest
DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Earnings To Watch: DexCom (DXCM) Reports Q2 Results Tomorrow - Yahoo Finance
2.06%
0.99%
자본화:
|
볼륨(24시간):